{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-25-004514","form_type":"8-K","ticker":"INCY","cik":"0000879169","company_name":"INCYTE CORP","filed_at":"2025-02-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:06.626370+00:00","generated_at":"2026-05-27T00:42:07.267253+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Incyte Q4 2024 revenue $1.18B (+16% YoY), guides 2025 Jakafi $2.93-2.98B, Opzelura $630-670M","bullets":["Q4 total revenues $1.18B (+16% YoY); full year $4.24B (+15%). GAAP diluted EPS $1.02 (Q4), $0.15 (FY); Non-GAAP $1.43 (Q4), $1.08 (FY).","Jakafi net revs Q4 $773M (+11% YoY), FY $2.79B (+8%); Opzelura Q4 $162M (+48%), FY $508M (+50%).","FY2025 guidance: Jakafi $2,925-2,975M; Opzelura $630-670M; other oncology $415-455M.","Pipeline catalysts: Niktimvo launched; ruxolitinib XR bioequivalence met, submission by year-end 2025; four pivotal readouts in 2025.","Cash and securities $2.2B at Dec 31, 2024, down from $3.7B due to $2B share repurchase and $783M Escient acquisition."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-25-004514","json":"https://secwatch.observer/filing/0001628280-25-004514.json","markdown":"https://secwatch.observer/filing/0001628280-25-004514.md","text":"https://secwatch.observer/filing/0001628280-25-004514.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/879169/000162828025004514/0001628280-25-004514-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/879169/000162828025004514/incy-20250210.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-27T00:42:07.267253+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}